| Basics |
Merus N.V.
Merus NV is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics.
|
| IPO Date: |
May 19, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$7.16B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.62 | 2.72%
|
| Avg Daily Range (30 D): |
$0.51 | 0.70%
|
| Avg Daily Range (90 D): |
$0.80 | 1.26%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.27M |
| Avg Daily Volume (30 D): |
3.39M |
| Avg Daily Volume (90 D): |
1.52M |
| Trade Size |
| Avg Trade Size (Sh.): |
87 |
| Avg Trade Size (Sh.) (30 D): |
137 |
| Avg Trade Size (Sh.) (90 D): |
102 |
| Institutional Trades |
| Total Inst.Trades: |
2,897 |
| Avg Inst. Trade: |
$2.34M |
| Avg Inst. Trade (30 D): |
$4.23M |
| Avg Inst. Trade (90 D): |
$3.79M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.47M |
| Avg Closing Trade (30 D): |
$6.71M |
| Avg Closing Trade (90 D): |
$4.75M |
| Avg Closing Volume: |
50.35K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-2.23
|
$-1.4
|
|
Diluted EPS
|
|
$-2.23
|
$-1.4
|
|
Revenue
|
$
|
$ 8.83M
|
$ 26.49M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -158.22M
|
$ -96.47M
|
|
Operating Income / Loss
|
$
|
$ -110.35M
|
$ -75.74M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 245.63M
|
$ -96.14M
|
|
PE Ratio
|
|
|
|
|
|
|
